Ezetimibe

Ezetimibe is prescribed to treat:

• Lowering cholesterol, often combined with statins • Various related conditions in the cardiovascular category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Ezetimibe (Zetia) is a cholesterol absorption inhibitor used for hypercholesterolemia and mixed hyperlipidemia. It works by a mechanism entirely different from the statins, which makes it the natural addition when a statin alone is not enough and the natural substitute when statins cannot be tolerated.

Mechanism of Action

Ezetimibe inhibits the Niemann-Pick C1-Like 1 transporter in the brush border of the small intestine, which mediates absorption of dietary and biliary cholesterol. Blocking it reduces cholesterol delivery to the liver.

The liver responds to reduced cholesterol delivery by upregulating LDL receptors, which then clear more LDL from the circulation — the same final step through which statins work, reached by a different route. This is why the two are complementary rather than redundant: statins reduce synthesis, ezetimibe reduces absorption, and combining them addresses both sources.

Alone, ezetimibe lowers LDL by roughly 15 to 20 percent, which is modest compared with a statin. Added to a statin it produces a further reduction of similar magnitude — and importantly, adding ezetimibe to a moderate-intensity statin often achieves what doubling the statin dose would not, since each doubling of statin dose adds only around 6 percent further LDL reduction.

The IMPROVE-IT trial demonstrated that adding ezetimibe to a statin reduced cardiovascular events, which established that the benefit follows the LDL reduction rather than being specific to statins. That finding underpins the current approach of treating to an LDL target by whatever combination achieves it.

Clinical Use

Ezetimibe is used as add-on therapy when maximum tolerated statin therapy leaves LDL above target, particularly in secondary prevention where targets are lower. It is used as monotherapy in genuine statin intolerance, and in combination in familial hypercholesterolemia.

Its principal practical advantage is tolerability. Ezetimibe does not cause the muscle symptoms that lead patients to abandon statins, and it has minimal drug interactions. In a patient who has stopped two statins because of myalgia, ezetimibe is a reasonable option that will at least deliver partial LDL reduction where the alternative is none at all.

Where it sits relative to newer agents matters. For patients requiring large further LDL reductions, PCSK9 inhibitors and inclisiran achieve far more than ezetimibe, but are injectable and considerably more expensive. Ezetimibe is oral, inexpensive as a generic, and is generally tried first. Bempedoic acid is another oral option, particularly in statin intolerance.

Statin intolerance itself deserves scrutiny before ezetimibe is substituted. Muscle symptoms attributed to statins frequently occur at similar rates on placebo in blinded trials, and a structured rechallenge — a different statin, a lower dose, or intermittent dosing — succeeds more often than expected. Pravastatin and rosuvastatin are the usual alternatives when atorvastatin has failed. The statins guide addresses the questions patients raise, and our cardiovascular team manages lipid targets alongside overall risk.

Monitoring and Follow-Up

Check a lipid panel at baseline and 4 to 12 weeks after starting or changing therapy, then every 6 to 12 months once stable. The expected additional LDL reduction from adding ezetimibe is predictable enough that falling well short of it points to adherence rather than non-response.

Liver enzymes warrant checking, particularly when ezetimibe is combined with a statin, since transaminase elevation is more common with the combination than with either alone. Routine creatine kinase monitoring is not required.

Ezetimibe is generally very well tolerated. Muscle symptoms are reported but at rates close to placebo, and diarrhoea and abdominal discomfort are the more typical complaints. It has few interactions, though bile acid sequestrants reduce its absorption and should be separated by several hours, and cyclosporine raises its levels.

The broader monitoring question is whether the LDL target is being reached at all. A substantial proportion of patients in secondary prevention remain above target on statin monotherapy without anyone adding a second agent — combination therapy is under-used relative to what guidelines support. The MedlinePlus ezetimibe entry covers prescribing detail, and the American Heart Association cholesterol resource provides patient-level context on targets.

The combination tablet with simvastatin is worth knowing about, since patients sometimes take it without realising it contains two drugs. It offers convenience and a single copay, at the cost of losing the ability to titrate each component independently — which matters because simvastatin has dose limits when combined with several common drugs including amlodipine and diltiazem. For most patients, separate tablets of ezetimibe and a statin chosen on its own merits is the more flexible arrangement.

Special Populations

In older adults ezetimibe is well tolerated and its favourable interaction profile is a genuine advantage in polypharmacy. No dose adjustment is needed in kidney impairment or mild hepatic impairment; moderate to severe hepatic impairment is a contraindication when combined with a statin, and ezetimibe is not recommended in that setting.

In pregnancy and breastfeeding, lipid-lowering therapy is generally stopped, since the benefit accrues over decades and the exposure is avoidable. Women of reproductive potential should discuss this. In children, ezetimibe is used in familial hypercholesterolemia from age 10 alongside a statin.

Lifestyle measures remain the foundation regardless of medication — a Mediterranean-style diet, regular activity, weight management, and smoking cessation compound with pharmacologic LDL reduction rather than being displaced by it. The Mediterranean diet article covers the dietary evidence.

When to Contact Your Doctor

Report new muscle pain, tenderness, or weakness, particularly if you also take a statin — while ezetimibe alone rarely causes this, the combination warrants assessment.

Report yellowing of the skin or eyes, dark urine, persistent right upper abdominal pain, or unusual fatigue, which may indicate liver injury. Report persistent diarrhoea or abdominal discomfort.

If you stopped a statin because of side effects and were started on ezetimibe alone, it is worth revisiting whether a statin rechallenge is possible, since the cardiovascular benefit of reaching target is substantially greater than what ezetimibe achieves by itself.

To review your lipid panel, discuss whether you have reached your LDL target, or address statin intolerance, contact us or schedule a visit.